Search

Your search keyword '"John M. Nakayama"' showing total 5 results
Start Over Author "John M. Nakayama"
5 results on '"John M. Nakayama"'

1. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Dimitrios Farmakiotis, Susie Owenby, Arturo Loaiza-Bonilla, Mansi R. Shah, Matthew Puc, Vadim S. Koshkin, Ahmad Daher, Prakash Peddi, Cameron Rink, Heloisa P. Soares, Eneida R. Nemecek, Mehmet Asim Bilen, Sanjay Mishra, Lidia Schapira, Amit Verma, Ali Raza Khaki, Chih-Yuan Hsu, Sandy DiLullo, Mark Bonnen, Jeanna Knoble, Carla Casulo, Umit Topaloglu, Jorge A. Garcia, Geoffrey Shouse, Praveen Vikas, Clarke A. Low, Archana Ajmera, George D. Demetri, Leyre Zubiri, Grace Glace, Shannon K. McWeeney, Susan Yackzan, Pamela C Egan, Rachel P. Rosovsky, Salvatore Del Prete, Anthony P. Gulati, Lane R. Rosen, Andy Futreal, Merry Jennifer Markham, Sabitha Prabhakaran, Alicia K. Morgans, Sarah Nagle, Lisa Weissmann, Albert C. Yeh, Ziad Bakouny, Stephanie Berg, David Gill, Marcus Messmer, Ryan Nguyen, Terence Duane Rhodes, Vikram M. Narayan, Matthew D. Galsky, Arielle Elkrief, Lori J. Rosenstein, Roy S. Herbst, Justin Shaya, Thorvardur R. Halfdanarson, Douglas B. Johnson, Orestis A. Panagiotou, Sanjay G. Revankar, Toni K. Choueiri, Yu Shyr, Fiona Busser, Kaitlin M. Kelleher, Nicole M. Kuderer, Paul L. Weinstein, Anup Kasi, Grace Shaw, Adam J. Olszewski, Catherine Curran, Samuel M. Rubinstein, Angelo Cabal, Michael H. Bar, John F. Deeken, Vivek Subbiah, Abdul Hai Mansoor, Hina Khan, Rana R. McKay, Catherine Stratton, Saurabh Dahiya, Marc A. Rovito, John Philip, Sanjay Shete, Oscar K. Serrano, Julie Fu, Daniel W. Bowles, Candice Schwartz, Tian Zhang, Pier Vitale Nuzzo, Eric H. Bernicker, Wenxin Xu, Genevieve M. Boland, Sarah Wall, Babar Bashir, Solange Peters, Neeta K. Venepalli, Sandeep H. Mashru, William A. Wood, Anne H. Angevine, Mary F. Mulcahy, Gilberto Lopes, Justin F. Gainor, Jessica Hawley, Monika Joshi, Christopher R. Friese, Navid Hafez, Heather H. Nelson, Gregory J. Riely, Jordan Kharofa, Nilo Azad, Chintan Shah, Gerald Batist, Mary Salazar, Rosemary Zacks, Alice Zhou, Lawrence E. Feldman, Paul Fu, Gary H. Lyman, Nathaniel Bouganim, John A. Steinharter, Shilpa Gupta, Matthias Weiss, Peter Paul Yu, Susan Van Loon, Jamie Stratton, Karen Vega-Luna, Tyler Masters, Christopher Lemmon, Aakash Desai, Bryan A. Faller, Jessica M. Clement, Zhuoer Xie, Keith Stockerl-Goldstein, Corrie A. Painter, Gabrielle Bouchard, Rulla M. Tamimi, Daruka Mahadevan, Rimma Belenkaya, Jill S. Barnholtz-Sloan, Jarushka Naidoo, Amelie G. Ramirez, Philip E. Lammers, Elizabeth A. Griffiths, Michael J. Gurley, X. Li, Jonathan Riess, Syed A. Ahmad, Daniel Blake Flora, Salma K. Jabbour, Jared D. Acoba, Neeraj Agarwal, Ang Li, Sarah Mushtaq, Firas Wehbe, Tanios Bekaii-Saab, Donald C. Vinh, Emily Hsu, Ryan Monahan, Petros Grivas, Harry Menon, John M. Nakayama, Janice M. Mehnert, Elizabeth Marie Wulff-Burchfield, Sara Matar, Paul E. Oberstein, Mary M. Pasquinelli, Axel Grothey, Jack West, John C. Leighton, Dawn L. Hershman, Leslie A. Fecher, Aditya Bardia, Sumit A. Shah, Barbara Logan, Kerry L. Reynolds, Michael A. Thompson, Robert L. Rice, Erin Cook, Trisha Wise-Draper, Christine Bestvina, Daniel Castellano, Paolo Caimi, K. M.Steve Lo, Ruben A. Mesa, Maheen Z. Abidi, Alvaro G. Menendez, Daniel G. Stover, Colleen Lewis, Bertrand Routy, Deborah B. Doroshow, Carmen C. Solorzano, M. Wasif Saif, Rohit Bishnoi, Michael Glover, David D. Chism, Briana Barrow, Christopher McNair, Dimpy P. Shah, Erin A. Gillaspie, Andrea J. Zimmer, Andrew Schmidt, Jessica K. Altman, Michelle Marcum, Rawad Elias, Balazs Halmos, Karen Stauffer, Gayathri Nagaraj, Ardaman Shergill, Mark E. Dailey, Catherine Handy Marshall, Pramod K. Srivastava, Shuchi Gulati, Alokkumar Jha, Mateo Bover Larroya, Mark A. Lewis, Young Soo Rho, James L. Chen, Eli Van Allen, Julie Tsu Yu Wu, Antonio Giordano, Amit Kulkarni, Joerg Rathmann, Donna R. Rivera, Narjust Duma, Maryam B. Lustberg, Theresa M. Carducci, Jeremy L. Warner, Elizabeth Robilotti, Patricia LoRusso, Rohit Jain, Amit Sanyal, Nizar M. Tannir, Kent Hoskins, Nathan A. Pennell, Brian I. Rini, Suki Subbiah, COVID-19 and Cancer Consortium, Abidi, M., Acoba, J.D., Agarwal, N., Ahmad, S., Ajmera, A., Altman, J., Angevine, A.H., Azad, N., Bar, M.H., Bardia, A., Barnholtz-Sloan, J., Barrow, B., Bashir, B., Belenkaya, R., Berg, S., Bernicker, E.H., Bestvina, C., Bishnoi, R., Boland, G., Bonnen, M., Bouchard, G., Bowles, D.W., Busser, F., Cabal, A., Caimi, P., Carducci, T., Casulo, C., Chen, J.L., Clement, J.M., Chism, D., Cook, E., Curran, C., Daher, A., Dailey, M., Dahiya, S., Deeken, J., Demetri, G.D., DiLullo, S., Duma, N., Elias, R., Faller, B., Fecher, L.A., Feldman, L.E., Friese, C.R., Fu, P., Fu, J., Futreal, A., Gainor, J., Garcia, J., Gill, D.M., Gillaspie, E.A., Giordano, A., Glace, M.G., Grothey, A., Gulati, S., Gurley, M., Halmos, B., Herbst, R., Hershman, D., Hoskins, K., Jain, R.K., Jabbour, S., Jha, A., Johnson, D.B., Joshi, M., Kelleher, K., Kharofa, J., Khan, H., Knoble, J., Koshkin, V.S., Kulkarni, A.A., Lammers, P.E., Leighton, J.C., Lewis, M.A., Li, X., Li, A., Lo, KMS, Loaiza-Bonilla, A., LoRusso, P., Low, C.A., Lustberg, M.B., Mahadevan, D., Mansoor, A.H., Marcum, M., Markham, M.J., Handy Marshall, C., Mashru, S.H., Matar, S., McNair, C., McWeeney, S., Mehnert, J.M., Menendez, A., Menon, H., Messmer, M., Monahan, R., Mushtaq, S., Nagaraj, G., Nagle, S., Naidoo, J., Nakayama, J.M., Narayan, V., Nelson, H.H., Nemecek, E.R., Nguyen, R., Nuzzo, P.V., Oberstein, P.E., Olszewski, A.J., Owenby, S., Pasquinelli, M.M., Philip, J., Prabhakaran, S., Puc, M., Ramirez, A., Rathmann, J., Revankar, S.G., Rho, Y.S., Rhodes, T.D., Rice, R.L., Riely, G.J., Riess, J., Rink, C., Robilotti, E.V., Rosenstein, L., Routy, B., Rovito, M.A., Saif, M.W., Sanyal, A., Schapira, L., Schwartz, C., Serrano, O., Shah, M., Shah, C., Shaw, G., Shergill, A., Shouse, G., Soares, H.P., Solorzano, C.C., Srivastava, P.K., Stauffer, K., Stover, D.G., Stratton, J., Stratton, C., Subbiah, V., Tamimi, R., Tannir, N.M., Topaloglu, U., Van Allen, E., Van Loon, S., Vega-Luna, K., Venepalli, N., Verma, A.K., Vikas, P., Wall, S., Weinstein, P.L., Weiss, M., Wise-Draper, T., Wood, W.A., Xu, W.V., Yackzan, S., Zacks, R., Zhang, T., Zimmer, A.J., and West, J.

Subjects
Prognostic variable, medicine.medical_specialty, business.industry, Cancer, General Medicine, Odds ratio, Aged, Antiviral Agents/therapeutic use, Azithromycin/therapeutic use, Betacoronavirus, Cause of Death, Comorbidity, Coronavirus Infections/drug therapy, Coronavirus Infections/epidemiology, Coronavirus Infections/mortality, Databases, Factual, Female, Humans, Hydroxychloroquine/therapeutic use, Male, Middle Aged, Neoplasms/epidemiology, Neoplasms/mortality, Neoplasms/therapy, Pandemics, Pneumonia, Viral/drug therapy, Pneumonia, Viral/epidemiology, Pneumonia, Viral/mortality, Prognosis, Risk Factors, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Cohort, Clinical endpoint, Medicine, 030212 general & internal medicine, business, Cause of death, Cohort study
Abstract

Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing. Findings Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57–76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53–2·21), male sex (1·63, 1·07–2·48), smoking status (former smoker vs never smoked: 1·60, 1·03–2·47), number of comorbidities (two vs none: 4·50, 1·33–15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11–7·18), active cancer (progressing vs remission: 5·20, 2·77–9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79–4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07–0·84) or the US-Midwest (0·50, 0·28–0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. Interpretation Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments. Funding American Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020
Full Text
View/download PDF

2. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study

Author

Ursula A. Matulonis, Helen Q. Huang, Virginia L. Filiaci, Marcus Randall, Paul A. DiSilvestro, Katherine M. Moxley, Jeffrey M. Fowler, Matthew A. Powell, Nick M. Spirtos, Krishnansu S. Tewari, William E. Richards, John M. Nakayama, David G. Mutch, David S. Miller, Daniela Matei, and Lari B. Wenzel

Subjects
Paclitaxel, Gastrointestinal Diseases, Obstetrics and Gynecology, Peripheral Nervous System Diseases, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Article, Carboplatin, Endometrial Neoplasms, Functional Status, Oncology, Chemotherapy, Adjuvant, Quality of Life, Humans, Female, Patient Reported Outcome Measures, Cisplatin, Neoplasm Staging
Abstract

INTRODUCTION: Chemotherapy plus radiation (Cis-RT+CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX) and psychometric properties of the gastrointestinal (GI) symptoms subscale during treatment and up to 1 year are described herein. METHODS: QOL assessments were scheduled at baseline, 6 weeks (post completion of RT (Cis-RT+CP) or prior to cycle 3 (CP)), then 18 weeks (end of treatment) and 70 weeks (1 year after the end of treatment) after starting treatment. QOL instruments included the FACT-En TOI, FACT/GOG-neurotoxicity (Ntx) subscale (short), and the gastrointestinal (GI) symptoms subscale. RESULTS: At the end of treatment, patients receiving Cis-RT+CP reported a statistically significant decreased QOL when compared to CP. The decline in QOL was reflected in physical well-being, functional well-being, and endometrial cancer specific concerns, but the minimally important differences (MID) were not considered clinically meaningful. Patients in both groups reported increased chemotherapy-induced Ntx symptoms with the CP group having worse scores and reaching peak symptoms at the time of chemotherapy completion. Patients on Cis-RT+CP reported statistically significantly worse GI symptoms after radiation therapy compared to patients on CP, this occurred across assessment intervals, though the MID was not meaningful. Psychometric evaluations indicated that the GI symptom scale is reliable, valid, and responsive to change. CONCLUSIONS: PROs indicate that the chemoradiotherapy group experienced worse HRQoL and GI toxicity compared to patients randomized to chemotherapy alone for locally advanced endometrial cancer though based on the MID, these were not clinically meaningful differences. The GI symptom subscale was a reliable and valid scale that has value for future trials.

Published
2021

3. Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium

Author

Deepak Ravindranathan, T. S. Bekaii-Saab, Minh-Phuong Huynh-Le, Stephanie Berg, David Gill, C. Hennessy, Shuchi Gulati, Zhuoer Xie, Keith Stockerl-Goldstein, Ang Li, Clarke A. Low, D. Y. Reuben, Emily Hsu, Sharad Goyal, Petros Grivas, Chih-Yuan Hsu, D. J. Hausrath, Jessica Hawley, Harry Menon, Huili Zhu, A. Jayaraj, Barry Dixon, Rachel P. Rosovsky, Benjamin French, L. Tachiki, A. J. Piper-Vallillo, Dimitrios Farmakiotis, Daniel Kwon, Susan Halabi, Thorvardur R. Halfdanarson, Gary H. Lyman, Astha Thakkar, Arturo Loaiza-Bonilla, A. Fazio, Sumit A. Shah, Mehmet Asim Bilen, Michael A. Thompson, X. Li, Suki Subbiah, Matthias Weiss, Catherine Curran, E. Tadesse, Christopher McNair, Matthew Puc, Prakash Peddi, Corrie A. Painter, Ali Raza Khaki, Donna R. Rivera, Maryam B. Lustberg, Eric H. Bernicker, Vadim S. Koshkin, A. Nizam, M. Streckfuss, Alice Zhou, Aakash Desai, Sunny R K Singh, John M. Nakayama, Leslie A. Fecher, Samuel M. Rubinstein, Gd L. Lopes, Philip E. Lammers, Yu Shyr, Jaymin M. Patel, J. Crowell, Sanjay Mishra, Anup Kasi, Donald C. Vinh, Leyre Zubiri, Jeremy L. Warner, Nathan A. Pennell, V. Mico, Rana R. McKay, Amit Verma, M. E. Reeves, Daniel W. Bowles, Cathleen Park, Jared D. Acoba, David D. Chism, Gayathri Nagaraj, Matthew D. Galsky, Arielle Elkrief, M. Smits, Kripa Patel, N. L. Nock, Chinmay Jani, Clara Hwang, Mansi R. Shah, Angelo Cabal, Eric B. Durbin, Brian I. Rini, Peter Paul Yu, Tian Zhang, Dimpy P. Shah, M. Salazar, Shilpa Gupta, Lori J. Rosenstein, Christopher R. Friese, Gary K. Schwartz, Andrew Schmidt, Daniel Blake Flora, Justin Shaya, P. Bindal, D. Mundt, Julie Fu, Matthew D Tucker, Trisha Wise-Draper, Toni K. Choueiri, Deborah B. Doroshow, Rohit Bishnoi, E. Wulff-Burchfield, Balazs Halmos, Chintan Shah, Babar Bashir, Solange Peters, Nathaniel Bouganim, Paolo Caimi, Ruben A. Mesa, Maheen Z. Abidi, Daniel G. Stover, Nicole M. Kuderer, Michael Glover, Jia Wu, Punita Grover, Shirish M. Gadgeel, E. S. Nakasone, Douglas B. Johnson, Hina Khan, and Ziad Bakouny

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Laboratory measurements, Disease, neoplasm, law.invention, Cancer, 03 medical and health sciences, COVID-19 Testing, 0302 clinical medicine, law, Neoplasms, Internal medicine, medicine, Humans, Outcomes, Pandemics, Etoposide, Aged, Chemotherapy, SARS-CoV-2, business.industry, COVID-19, Hematology, medicine.disease, Intensive care unit, Clinical trial, 030104 developmental biology, Oncology, Anti-cancer therapy, 030220 oncology & carcinogenesis, Cohort, SARS-CoV2, Absolute neutrophil count, Female, Original Article, business, medicine.drug
Abstract

BACKGROUND: Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies. PATIENTS AND METHODS: Patients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demographics, cancer status, anticancer therapy and timing, COVID-19-directed therapies, and laboratory measurements (among hospitalized patients). RESULTS: A total of 4966 patients were included (median age 66 years, 51% female, 50% non-Hispanic white); 2872 (58%) were hospitalized and 695 (14%) died; 61% had cancer that was present, diagnosed, or treated within the year prior to COVID-19 diagnosis. Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance status, recent cytotoxic chemotherapy, and hematologic malignancy were associated with higher COVID-19 severity. Among hospitalized patients, low or high absolute lymphocyte count; high absolute neutrophil count; low platelet count; abnormal creatinine; troponin; lactate dehydrogenase; and C-reactive protein were associated with higher COVID-19 severity. Patients diagnosed early in the COVID-19 pandemic (January-April 2020) had worse outcomes than those diagnosed later. Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, and DNA methyltransferase inhibitors) were associated with high 30-day all-cause mortality. CONCLUSIONS: Clinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further studies are needed, caution may be required in utilizing particular anticancer therapies. CLINICAL TRIAL IDENTIFIER: NCT04354701.

Published
2021

4. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Sarah Wall, Babar Bashir, Toni K. Choueiri, Salvatore Del Prete, Grace Shaw, Solange Peters, Catherine Curran, Navid Hafez, Nathaniel Bouganim, Sarah Nagle, Julie Tsu-Yu Wu, Jared D. Acoba, Vaibhav Kumar, Gabrielle Bouchard, Lisa Weissmann, Hagen F. Kennecke, Tian Zhang, Manmeet Ahluwalia, Sanjay Goel, Samuel M. Rubinstein, Daruka Mahadevan, Elizabeth A. Griffiths, Destry J. Elms, Michael J. Gurley, Arturo Loaiza-Bonilla, Suki Subbiah, Gilberto Lopes, Lisa Tachiki, David M. Aboulafia, Kent Hoskins, Daniel W. Bowles, Sandeep H. Mashru, Matthew Puc, Prakash Peddi, Nathan A. Pennell, Stephen V. Liu, Justin F. Gainor, Ali Raza Khaki, Rebecca L. Zon, Matthew D Tucker, Amanda Nizam, Bryan A. Faller, Deborah B. Doroshow, Nitin Ohri, Brian I. Rini, Abdul-Hai Mansoor, Sachin R. Jhawar, George D. Demetri, Catherine Stratton, Eliezer M. Van Allen, Praveen Vikas, Alvaro G. Menendez, Amelie G. Ramirez, Jonathan M. Loree, Divaya Bhutani, Clarke A. Low, Anju Nohria, Melissa K. Accordino, Rohit Bishnoi, Pamela C Egan, Rachel P. Rosovsky, Julie C. Fu, Fiona Busser, Orestis A. Panagiotou, Aditya Bardia, Peter Paul Yu, Susan Van Loon, Genevieve M. Boland, Douglas B. Johnson, Anup Kasi, Barbara Logan, Alice Zhou, Matthew D. Galsky, Arielle Elkrief, Mary Salazar, Rosemary Zacks, Carmen C. Solorzano, Andrew Schmidt, Paolo Caimi, Zhuoer Xie, Michael T. Schweizer, Briana Barrow McCollough, Jessica K. Altman, Christopher McNair, Cassandra Hennessy, Angelo Cabal, Qamar Ul Zaman, Alex Cheng, Keith Stockerl-Goldstein, John C. Leighton, Joshua D. Palmer, Scott J. Dawsey, Deepak Ravindranathan, Jonathan Riess, Miriam Santos Dutra, Daniel Blake Flora, Aakash Desai, Rana R. McKay, Ruben A. Mesa, Maheen Z. Abidi, Cathleen Park, Jill S. Barnholtz-Sloan, Erin Cook, Trisha Wise-Draper, Shannon K. McWeeney, Donald C. Vinh, Clara Hwang, Stephanie Berg, Leyre Zubiri, Daniel G. Stover, Michelle Marcum, Sarah Mushtaq, Wilhelmina D. Cabalona, Eyob Tadesse, Kanishka G. Patel, Ryan Monahan, Ziad Bakouny, Pankil Shah, David Gill, Terence Duane Rhodes, Marc A. Rovito, Chih-Yuan Hsu, Elizabeth T. Loggers, Shilpa Gupta, Susie Owenby, Benjamin A. Gartrell, David D. Chism, Neeta K. Venepalli, Punita Grover, Adam J. Olszewski, Sonya A. Reid, Firas Wehbe, Omar Butt, Emily Hsu, Poorva Bindal, Paul L. Weinstein, Jessica Hawley, Tanya M. Wildes, Subha Madhavan, Claire Hoppenot, Margaret E. Gatti-Mays, Huili Zhu, Michael Glover, Rawad Elias, Elizabeth S. Nakasone, Heather H. Nelson, Gerald Batist, Gary H. Lyman, John F. Deeken, Michael H. Bar, Pamela Bohachek, Benjamin French, Mark A. Lewis, Daniel J. Hausrath, Mary F. Mulcahy, X. Li, David A. Slosky, Michael J. Wagner, Nicole Williams, Hina Khan, Grace Glace, Jessica M. Clement, Pier Vitale Nuzzo, Petros Grivas, Brett A. Schroeder, Tanios Bekaii-Saab, John M. Nakayama, Vasil Mico, Young Soo Rho, Chaim Miller, Amit Verma, Kaitlin M. Kelleher, Elwyn C. Cabebe, William A. Wood, Elizabeth J. Davis, Anne H. Angevine, Cristiano Ferrario, Shaveta Vinayak, Jerome J. Graber, Monika Joshi, Danielle A. Shafer, Mary M. Pasquinelli, Mark Bonnen, Shirish M. Gadgeel, Balazs Halmos, Lucy L. Wang, Dawn L. Hershman, Sana Z. Mahmood, Dimpy P. Shah, Maryam B. Lustberg, Albert C. Yeh, Eric H. Bernicker, Mitrianna Streckfuss, Leslie A. Fecher, Clement Pillainayagam, Karen Stauffer, Gayathri Nagaraj, Dimitrios Farmakiotis, Elizabeth Marie Wulff-Burchfield, Chintan Shah, Sibel Blau, Ryan H. Nguyen, Lane R. Rosen, Robert L. Rice, Mark E. Dailey, Melanie J. Clark, Goetz Kloecker, Alicia K. Morgans, Cameron Rink, Umit Topaloglu, Mark A. Fiala, Saif I. Alimohamed, Gary K. Schwartz, Jessica Yasmine Islam, Bertrand Routy, James L. Chen, Oscar K. Serrano, Chinmay Jani, Shuchi Gulati, K.M. Lo, Alokkumar Jha, Anthony P. Gulati, Lori J. Rosenstein, Roy S. Herbst, Matthias Weiss, Justin Shaya, Philip E. Lammers, Irene S. Yu, Syed A. Ahmad, Salma K. Jabbour, Erin A. Gillaspie, Irma Hoyo-Ulloa, Jordan Kharofa, Jean M. Connors, Daniel Mundt, Christopher R. Friese, Ryan C. Lynch, Mansi R. Shah, Howard Zaren, M. Wasif Saif, Gerald Gantt, Lawrence E. Feldman, Jian Campian, Daniel Y. Reuben, Sanjay G. Revankar, Merry Jennifer Markham, Melissa Smits, Patricia LoRusso, Thorvardur R. Halfdanarson, Christine Pilar, Eric B. Durbin, Blanche Mavromatis, Yu Shyr, Jaymin M. Patel, Candice Schwartz, Ang Li, Antonio Giordano, Amit Kulkarni, Joerg Rathmann, Harry Menon, Amro Elshoury, Mahir Khan, Theresa M. Carducci, Susan Halabi, Sumit A. Shah, Jeremy L. Warner, Mehmet Asim Bilen, Kerry L. Reynolds, Michael A. Thompson, Ahmad Daher, Lidia Schapira, Eneida R. Nemecek, Sanjay Mishra, Jamie Stratton, Karen Vega-Luna, Tyler Masters, Corrie A. Painter, Archana Ajmera, Jorge A. Garcia, Wenxin Xu, Christopher Lemmon, and Jeanna Knoble

Subjects
0301 basic medicine, Cancer Research, Quality management, MEDLINE, 03 medical and health sciences, COVID-19 Testing, 0302 clinical medicine, Neoplasms, Pandemic, medicine, Electronic Health Records, Humans, Protocol (science), SARS-CoV-2, business.industry, Corporate governance, COVID-19, Cancer, Cell Biology, medicine.disease, Quality Improvement, Data Accuracy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Scale (social sciences), Commentary, Business, Medical emergency, Quality assurance
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020
Full Text
View/download PDF

5. A case report of adult croup: a new old problem

Author

John M, Nakayama and Jinichi, Tokeshai

Subjects
Aged, 80 and over, Croup, Ceftriaxone, Humans, Female, Aged, Anti-Bacterial Agents
Abstract

Larnygeotracheobronchitis is a common disease of childhood most often associated with infection by parainfluenza virus. Although rare, adult cases have been reported. Adult croup presents similarly to the childhood version; however, the severity is usually much worse, often leading to hospitalization. Presented is the case of an 80-year-old woman with croup, which is the twelfth reported in the English literature.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results